Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Mixed Connective Tissue Disease: The Two Cases Representing the Range of this Illness

Author(s): Ashaq Hussain Parrey*, Manzoor Koka and Mohd Ismail

Volume 20, Issue 5, 2024

Published on: 23 January, 2024

Page: [569 - 573] Pages: 5

DOI: 10.2174/0115733971263972231124111042

Price: $65

Abstract

Introduction: Mixed connective tissue disease (MCTD) is defined as a systemic rheumatic disease characterized by the presence of high titer anti-U1 ribonucleoprotein (U1 RNP) antibodies in combination with clinical features commonly seen in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA) and polymyositis (PM).

Case Presentation: The annual incidence of MCTD is 1.9 per 100,000 adults. Any organ system can be involved in MCTD however four clinical features that suggest the presence of MCTD rather than another systemic rheumatic disease are Raynaud phenomenon with swollen hands or puffy fingers, absence of severe kidney disease and central nervous system (CNS) disease at first presentation generally, insidious onset of pulmonary hypertension and presence of autoantibodies anti-U1 ribonucleoprotein (U1 RNP), especially antibodies to the 68 kD protein. MCTD, although initially thought to be a disease with a benign course is not considered a valid argument at present. This connective tissue disorder can present with life-threating organ involvement with rapid progression of disease.

Conclusion: We report two cases of MCTD, one with mild disease and another with life-threatening illness, describing the range of severity at presentation of this disorder.

« Previous Next »
Graphical Abstract

[1]
Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52(2): 148-59.
[http://dx.doi.org/10.1016/0002-9343(72)90064-2] [PMID: 4621694]
[2]
Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus related diseases. Lupus 2011; 21(3): 148-59.
[PMID: 22065092]
[3]
Chaigne B, Scirè CA, Talarico R, et al. Mixed connective tissue disease: State of the art on clinical practice guidelines. RMD Open 2019; 4 (Suppl. 1): e000783.
[http://dx.doi.org/10.1136/rmdopen-2018-000783] [PMID: 30402271]
[4]
Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005; 31(3): 411-20.
[http://dx.doi.org/10.1016/j.rdc.2005.04.007] [PMID: 16084315]
[5]
Sapkota B, Al Khalili Y. Mixed connective tissue disease.StatPearls. Treasure Island, FL: StatPearls Publishing 2023. Updated 2023 Apr 3
[6]
Cappelli S, Randone S, Martinović D, et al. “To be or not to be,” ten years after: Evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41(4): 589-98.
[http://dx.doi.org/10.1016/j.semarthrit.2011.07.010] [PMID: 21959290]
[7]
Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989; 16(3): 328-34.
[PMID: 2724251]
[8]
Bennett RM, Spargo BH. Immune complex nephropathy in mixed connective tissue disease. Am J Med 1977; 63(4): 534-41.
[http://dx.doi.org/10.1016/0002-9343(77)90198-X] [PMID: 143887]
[9]
Venables PJ. Mixed connective tissue disease. Lupus 2006; 15(3): 132-7.
[http://dx.doi.org/10.1191/0961203306lu2283rr] [PMID: 16634365]
[10]
Kitridou RC, Akmal M, Turkel SB, Ehresmann GR, Quismorio FP Jr, Massry SG. Renal involvement in mixed connective tissue disease: A longitudinal clinicopathologic study. Semin Arthritis Rheum 1986; 16(2): 135-45.
[http://dx.doi.org/10.1016/0049-0172(86)90047-8] [PMID: 3563525]
[11]
Bennett RM, O’Connell DJ. Mixed connective tissue disease: A clinicopathologic study of 20 cases. Semin Arthritis Rheum 1980; 10(1): 25-51.
[http://dx.doi.org/10.1016/0049-0172(80)90013-X] [PMID: 7414333]
[12]
Maddison PJ, Mogavero H, Reichlin M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol 1978; 5(4): 407-11.
[PMID: 310884]
[13]
Gunnarsson R, Hetlevik SO, Lilleby V, Molberg Ø. Mixed connective tissue disease. Best Pract Res Clin Rheumatol 2016; 30(1): 95-111.
[http://dx.doi.org/10.1016/j.berh.2016.03.002] [PMID: 27421219]
[14]
Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med 1978; 65(6): 955-62.
[http://dx.doi.org/10.1016/0002-9343(78)90747-7] [PMID: 217265]
[15]
Bennett RM, O’Connell DJOC. Gastrointestinal systemic sclerosis in mixed connective tissue disease. Arthritis Rheum 1979; 22(4): 429.
[http://dx.doi.org/10.1002/art.1780220423] [PMID: 426890]
[16]
Hagen NA, Stevens JC, Michet CJ Jr. Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 1990; 40(6): 891-6.
[http://dx.doi.org/10.1212/WNL.40.6.891] [PMID: 2161090]
[17]
Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295(21): 1149-54.
[http://dx.doi.org/10.1056/NEJM197611182952101] [PMID: 1086429]
[18]
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182(18): E839-42.
[http://dx.doi.org/10.1503/cmaj.090449] [PMID: 20603348]
[19]
Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: A subsequent evaluation of the original 25 patients. Medicine 1980; 59(4): 239-48.
[http://dx.doi.org/10.1097/00005792-198007000-00001] [PMID: 6967141]
[20]
Miyawaki S, Onodera H. Clinical course and prognosis of patients with mixed connective tissue disease.Mixed Connective Tissue Disease and Antinuclear Antibodies. Amsterdam: Excerpta Medica 1987; p. 331.
[21]
Gendi NST, Welsh KI, Van Venrooij WJ, Vancheeswaran R, Gilroy J, Black CM. Hla type as a predictor of mixed connective tissue disease differentiation ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38(2): 259-66.
[http://dx.doi.org/10.1002/art.1780380216] [PMID: 7848317]
[22]
Szodoray P, Hajas A, Kardos L, et al. Distinct phenotypes in mixed connective tissue disease: Subgroups and survival. Lupus 2012; 21(13): 1412-22.
[http://dx.doi.org/10.1177/0961203312456751] [PMID: 22864236]
[23]
Hajas A, Szodoray P, Nakken B, et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 2013; 40(7): 1134-42.
[http://dx.doi.org/10.3899/jrheum.121272] [PMID: 23637328]
[24]
Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med 2010; 31(3): 433-49.
[http://dx.doi.org/10.1016/j.ccm.2010.05.004] [PMID: 20692538]
[25]
Végh J, Szilasi M, Soós G, et al. Interstitial lung disease in mixed connective tissue disease. Orv Hetil 2005; 146(48): 2435-43.
[PMID: 16408383]
[26]
Kozuka T, Johkoh T, Honda O. Pulmonary involvement in mixed connective tissue disease: High-resolution CT findings in 41 patients. J Thorac Imaging 2001; 16(2): 94-8.
[27]
Garaiman A, Jordan S, Distler O. Challenges in the management of mixed connective tissue disease: A retrospective analysis of the MCTD cohort in a tertiary referral centre Wanzenried A, Garaiman A, Jordan S, Distler O. Ann Rheum Dis 2021; 80: 1233.
[28]
Ungprasert P, Crowson CS, Chowdhary VR, Ernste FC, Moder KG, Matteson EL. Epidemiology of Mixed Connective Tissue Disease, 1985–2014: A Population-Based Study. Arthritis Care Res (Hoboken) 2016; 68(12): 1843-8.
[http://dx.doi.org/10.1002/acr.22872] [PMID: 26946215]
[29]
Reiseter S, Gunnarsson R, Corander J, et al. Disease evolution in mixed connective tissue disease: Results from a long-term nationwide prospective cohort study. Arthritis Res Ther 2017; 19(1): 284.
[http://dx.doi.org/10.1186/s13075-017-1494-7] [PMID: 29268795]
[30]
Van Den Hoogen FHJ, Spronk PE, Boerbooms AMT, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Rheumatology (Oxford) 1994; 33(12): 1117-20.
[http://dx.doi.org/10.1093/rheumatology/33.12.1117] [PMID: 8000737]
[31]
Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease.In: Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Amsterdam: Elsevier 1987; pp. 33-40.
[32]
Kashiwazaki S, Kondo H, Fukui T. Features of anti-nRNP antibody positive patients.In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsevier 1987; p. 261.
[33]
Leroy EC, Maricq HR, Kahaleh M. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980; 23(3): 341-3.
[http://dx.doi.org/10.1002/art.1780230312] [PMID: 7362686]
[34]
Bodolay E, Szegedi G. Undifferentiated connective tissue disease. Orv Hetil 2009; 150(19): 867-72.
[http://dx.doi.org/10.1556/OH.2009.28610] [PMID: 19403430]
[35]
Dunkley L. Comment on: A case of Raynaud's phenomenon in mixed connective tissue disease responding to Rituximab therapy response. Rheumatology (Oxford) 2007; 46(10): 1628-9.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy